It is supported from pre-clinical studies that complement repression prevents DKD progression, and targeting of the complement receptor could be a promising therapeutic strategy [22], as well as the use of antibodies against IgM and endoglin [30,31,32,51]. The gene discussed is CD40LG; the disease is diabetic kidney disease.